New immunotherapy cocktail shows promise against tough cancers
NCT ID NCT03482102
First seen May 14, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation therapy can shrink tumors in people with advanced liver cancer or bile duct cancer. About 37 adults whose cancer cannot be removed by surgery or has spread will receive the treatment. The goal is to see how many patients have their tumors shrink or disappear, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.